Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma

Abstract Background The aim of this study was to identify the long-term clinical outcome of definitive radiotherapy using three-dimensional conformal radiotherapy (3DCRT) for cervical esophageal squamous cell carcinoma (CESCC). Methods We retrospectively reviewed the medical records of 30 patients w...

Full description

Bibliographic Details
Main Authors: Katsuyuki Sakanaka, Yuichi Ishida, Kota Fujii, Satoshi Itasaka, Shin’ichi Miyamoto, Takahiro Horimatsu, Manabu Muto, Takashi Mizowaki
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Radiation Oncology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13014-018-0957-6
_version_ 1811281187716464640
author Katsuyuki Sakanaka
Yuichi Ishida
Kota Fujii
Satoshi Itasaka
Shin’ichi Miyamoto
Takahiro Horimatsu
Manabu Muto
Takashi Mizowaki
author_facet Katsuyuki Sakanaka
Yuichi Ishida
Kota Fujii
Satoshi Itasaka
Shin’ichi Miyamoto
Takahiro Horimatsu
Manabu Muto
Takashi Mizowaki
author_sort Katsuyuki Sakanaka
collection DOAJ
description Abstract Background The aim of this study was to identify the long-term clinical outcome of definitive radiotherapy using three-dimensional conformal radiotherapy (3DCRT) for cervical esophageal squamous cell carcinoma (CESCC). Methods We retrospectively reviewed the medical records of 30 patients with CESCC [clinical stage I/II/III/IV(M1LYM); 3/2/12/13] (TNM 7th edition) who underwent definitive radiotherapy using 3DCRT between 2000 and 2014 in our institution. The median prescribed dose for the gross tumor and metastatic lymph nodes was 60 Gy. Twenty-six patients underwent elective nodal irradiation for the neck node levels III, IV, and VI and for upper mediastinal lymph nodes with a median dose of 40 Gy. Twenty-six patients underwent concurrent chemotherapy. Initial disease progression sites, locoregional control (LRC) rate, overall survival (OS) rate, and toxicities were retrospectively evaluated. A univariate analysis was performed to identify prognostic factors. Results With a median follow-up of 110 months, the 5- and 10-year LRC rates were 43.7% and 37.4%, respectively. The 5- and 10-year OS rates were 48.3% and 40.2%, respectively. Locoregional, distant and both area accounted for 83%, 6% and 11% of the initial progression sites. Unresectable status and M1LYM were significantly associated with poor LRC (p < 0.05) and OS (p < 0.05). Grade 3 acute non-hematological toxicity occurred in 13.3% of patients. During the follow-up, patients without any disease progression did not need a permanent gastrostomy tube or tracheostomy. Late toxicity events, including hypothyroidism and cardiovascular disease, were observed; 5- and 10-year cumulative incidence rates of grade 2 hypothyroidism and ≥grade 3 cardiovascular disease were 31.6% and 62.5%, and 17.5% and 21.3%, respectively. Conclusions Definitive radiotherapy yields a cure for patients with CESCC while preserving their laryngopharyngeal function. The poor LRC rate in the advanced stage needs to be overcome for a better prognosis. As the incidence of radiation-induced hypothyroidism and cardiovascular disease was not low, long-term survivors should be followed up for these symptoms.
first_indexed 2024-04-13T01:28:57Z
format Article
id doaj.art-cef65f0cb5464da48cd8e806dc97aa65
institution Directory Open Access Journal
issn 1748-717X
language English
last_indexed 2024-04-13T01:28:57Z
publishDate 2018-01-01
publisher BMC
record_format Article
series Radiation Oncology
spelling doaj.art-cef65f0cb5464da48cd8e806dc97aa652022-12-22T03:08:34ZengBMCRadiation Oncology1748-717X2018-01-011311810.1186/s13014-018-0957-6Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinomaKatsuyuki Sakanaka0Yuichi Ishida1Kota Fujii2Satoshi Itasaka3Shin’ichi Miyamoto4Takahiro Horimatsu5Manabu Muto6Takashi Mizowaki7Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto UniversityDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto UniversityDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto UniversityDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto UniversityDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto UniversityDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto UniversityAbstract Background The aim of this study was to identify the long-term clinical outcome of definitive radiotherapy using three-dimensional conformal radiotherapy (3DCRT) for cervical esophageal squamous cell carcinoma (CESCC). Methods We retrospectively reviewed the medical records of 30 patients with CESCC [clinical stage I/II/III/IV(M1LYM); 3/2/12/13] (TNM 7th edition) who underwent definitive radiotherapy using 3DCRT between 2000 and 2014 in our institution. The median prescribed dose for the gross tumor and metastatic lymph nodes was 60 Gy. Twenty-six patients underwent elective nodal irradiation for the neck node levels III, IV, and VI and for upper mediastinal lymph nodes with a median dose of 40 Gy. Twenty-six patients underwent concurrent chemotherapy. Initial disease progression sites, locoregional control (LRC) rate, overall survival (OS) rate, and toxicities were retrospectively evaluated. A univariate analysis was performed to identify prognostic factors. Results With a median follow-up of 110 months, the 5- and 10-year LRC rates were 43.7% and 37.4%, respectively. The 5- and 10-year OS rates were 48.3% and 40.2%, respectively. Locoregional, distant and both area accounted for 83%, 6% and 11% of the initial progression sites. Unresectable status and M1LYM were significantly associated with poor LRC (p < 0.05) and OS (p < 0.05). Grade 3 acute non-hematological toxicity occurred in 13.3% of patients. During the follow-up, patients without any disease progression did not need a permanent gastrostomy tube or tracheostomy. Late toxicity events, including hypothyroidism and cardiovascular disease, were observed; 5- and 10-year cumulative incidence rates of grade 2 hypothyroidism and ≥grade 3 cardiovascular disease were 31.6% and 62.5%, and 17.5% and 21.3%, respectively. Conclusions Definitive radiotherapy yields a cure for patients with CESCC while preserving their laryngopharyngeal function. The poor LRC rate in the advanced stage needs to be overcome for a better prognosis. As the incidence of radiation-induced hypothyroidism and cardiovascular disease was not low, long-term survivors should be followed up for these symptoms.http://link.springer.com/article/10.1186/s13014-018-0957-6Esophageal NeoplasmsRadiotherapyConformalLong-term outcomeHypothyroidismCardiovascular disease
spellingShingle Katsuyuki Sakanaka
Yuichi Ishida
Kota Fujii
Satoshi Itasaka
Shin’ichi Miyamoto
Takahiro Horimatsu
Manabu Muto
Takashi Mizowaki
Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
Radiation Oncology
Esophageal Neoplasms
Radiotherapy
Conformal
Long-term outcome
Hypothyroidism
Cardiovascular disease
title Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
title_full Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
title_fullStr Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
title_full_unstemmed Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
title_short Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
title_sort long term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma
topic Esophageal Neoplasms
Radiotherapy
Conformal
Long-term outcome
Hypothyroidism
Cardiovascular disease
url http://link.springer.com/article/10.1186/s13014-018-0957-6
work_keys_str_mv AT katsuyukisakanaka longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT yuichiishida longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT kotafujii longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT satoshiitasaka longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT shinichimiyamoto longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT takahirohorimatsu longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT manabumuto longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma
AT takashimizowaki longtermoutcomeofdefinitiveradiotherapyforcervicalesophagealsquamouscellcarcinoma